三友医疗(688085) - 2025 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2025 reached ¥542.79 million, representing a year-on-year increase of 19.66%[3] - The net profit attributable to the parent company was ¥63.29 million, a significant increase of 451.85% compared to the previous year[3] - The basic earnings per share rose to ¥0.19, reflecting a growth of 375.00% year-on-year[3] - The company’s operating profit increased by 145.93% year-on-year, while total profit rose by 155.92%[7] Research and Development - Research and development expenses amounted to ¥83.71 million, accounting for 15.42% of total revenue[5] Assets and Equity - Total assets at the end of the reporting period were ¥2,376.83 million, up 3.04% from the beginning of the period[5] - The company’s equity attributable to the parent company increased by 10.10% to ¥2,104.89 million[5] - The company’s share capital grew by 34.22% due to a capital reserve conversion and the acquisition of remaining minority interests in a subsidiary[8] International Business - The company’s international business, particularly through its subsidiary Implanet, generated €12.47 million in revenue, a 32.62% increase, with the U.S. market growing by 49.30%[6] Stock Incentive Plan - The company implemented a stock incentive plan, resulting in share-based payment expenses of approximately ¥8.40 million[6]